Retrospective analyses versus RCTs: comparing like with like?

Ralf Baron1 Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital of Schleswig-Holstein, Kiel Campus, Kiel

Lieven Nils Kennes2 Department of Economics and Business Administration, University of Applied Sciences Stralsund, Stralsund

Christian Elling3 Grünenthal GmbH, Medical Affairs Europe and North America, Aachen, GermanyCorrespondence[email protected]

References

UeberallMAMueller-SchwefeGHHEfficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observationsJ Pain Res201691001102027881925
PubMed Web of Science ®Google Scholar
BaronRLikarRMartin-MolaEEffectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 studyPain Pract20161658059926095455
PubMed Web of Science ®Google Scholar
HanssonLHednerTDahlöfBProspective randomized open blinded end-point (PROBE) study. A novel design for intervention trialsBlood Press1992121131191366259
PubMedGoogle Scholar
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseICH Harmonised Tripartite Guideline. Statistical Principles for Clinical Trials E91998 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdfAccessed January 16, 2017
Google Scholar

UeberallMAMueller-SchwefeGHHEfficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observationsJ Pain Res201691001102027881925
PubMed Web of Science ®Google Scholar
BaronRLikarRMartin-MolaEEffectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 studyPain Pract201616558059926095455
PubMed Web of Science ®Google Scholar